Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation

Montone, Kathleen T.; Litzky, Leslie A.; Wurster, Angela; Kaiser, Larry R.; Bavaria, Joseph E.; Kotloff, Robert M.; Palevsky, Harold I.; Pietra, Giuseppe G.; Tomaszewski, John E.

doi:10.1016/s0039-6060(96)80265-0

Cited by 71 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, PTLDs in LTx patients appear to occur very early after transplant (median time 7 mo) compared with non-LTx patients (median time, 41 mo), which is consistent with the case in the previous literature (12,23,24,30). In addition, these PTLDs also appear to be clinically aggressive, with 5 of 8 patients dying of their PTLD.…”

Section: Discussionsupporting

confidence: 87%

“…The incidence of PTLD in LTx patients varies in the literature from 6 to 10% (12,24). Montone et al (23) reported a very high incidence of 20% that seems to be an outlier. It is of note that the cohort of transplant patients in that series was rather small (45 patients).…”

Section: Discussionmentioning

confidence: 99%

“…We recently encountered two PTLDs in LTx patients that occurred early after transplantation and demonstrated an aggressive clinical behavior. On review of the literature, we found a varied experience, with some reporting a high incidence of PTLD in LTx patients, whereas others found a much lower incidence (12,(22)(23)(24).…”

mentioning

confidence: 98%

“…Large series reporting the incidence and presentation of PTLDs exclusively in lung transplant (LTx) patients are few (12,(22)(23)(24). We recently encountered two PTLDs in LTx patients that occurred early after transplantation and demonstrated an aggressive clinical behavior.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

et al. 2002

View full text Add to dashboard Cite

PTLD is a well-recognized complication of organ transplantation. Large series of heart, renal, and liver transplants have been examined for the incidence and behavior of PTLD. However, reports of the incidence and characteristics of PTLDs in lung transplant (LTx) patients are few. We report our experience with PTLDs in a large series of LTx recipients at a single institution and compare them to other solid organ transplant recipient PTLDs seen at our institution. Twenty-eight patients were found to have PTLD, of whom 8 were lung transplant recipients. We evaluated nine PTLD specimens from these 8 patients for their histology, immunophenotype (CD20, CD3, EBV-LMP1), EBER status by in situ hybridization, and clinical features. The incidence of PTLD was 3.3% (8/244 patients). The time to development of PTLD, after transplant, was short (median time, 7 mo). All were of B-cell lineage. Overall, EBV was demonstrated in 77.7% (7 of 9 specimens) of PTLDs. All specimens tested for clonality were found to be monoclonal. Five patients died, with a median time to death of only 4.6 months. PTLDs in LTx patients are EBV-associated B-cell, predominantly monoclonal lymphoid lesions similar to other solid organ transplant PTLDs. Compared with other solid organ transplant recipients with PTLD at our institution, PTLDs in LTx patients have a propensity to involve the transplanted organ (P ‫؍‬ .001, Fisher's exact test), occur earlier after transplant (P ‫؍‬ .003, Wilcoxon test), and have a shorter survival (P ‫؍‬ .002, log rank test). Reasons for this may include the relatively higher level of immunosuppression required in these patients and limited options in decreasing it. Although the incidence is low, careful early monitoring of lung transplantation patients is warranted because of the poor prognosis of patients developing this complication.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 98%

mentioning

confidence: 99%

See 2 more Smart Citations

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

et al. 2002

View full text Add to dashboard Cite

show abstract

“…1 The reported incidence of PTLD in pulmonary transplant recipients varies from 1.6% to 20%, and is 2 to 6 times higher than that reported in other solid organ transplant recipients. [2][3][4] In addition to being more frequent, PTLD in lung transplant recipients occurs earlier after the transplantation and follows a more aggressive course. 5 Lymphomas affect about 2.3% of patients at 1 year and 0.97% of patients at 5 years after lung transplantation.…”

mentioning

confidence: 99%

Lung Retransplantation After Posttransplantation Lymphoproliferative Disorder (PTLD): A Single-Center Experience and Review of Literature of PTLD in Lung Transplant Recipients

Raj

Frost

2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti‐CD4 monoclonal antibodies and chronic alcohol consumption

Hunt

Robert

Zieske

et al. 2000

Cancer

View full text Add to dashboard Cite

Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation

Cited by 71 publications

References 25 publications

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic Experience

Lung Retransplantation After Posttransplantation Lymphoproliferative Disorder (PTLD): A Single-Center Experience and Review of Literature of PTLD in Lung Transplant Recipients

Orthotopic human lung carcinoma xenografts in BALB/c mice immunosuppressed with anti‐CD4 monoclonal antibodies and chronic alcohol consumption

Contact Info

Product

Resources

About